trending Market Intelligence /marketintelligence/en/news-insights/trending/wyzojglcdatme7uw0ubmyg2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

Nuformix adds nonexecutive director to board

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective

Blog

Corporate Credit Risk Trends in Developing Markets: A Probability of Default Perspective


Nuformix adds nonexecutive director to board

Nuformix PLC appointed Christopher Blackwell as a nonexecutive director of the company.

Blackwell served as the CEO of Vectura Group PLC from February 2004 to June 2015, taking the company through its initial IPO to a valuation of over $1 billion, Nuformix said in a statement.

Cambridge, U.K.-based Nuformix uses cocrystal technology to improve small molecule drugs.

Blackwell will assist the company as it develops its NXP002 programme for the treatment of fibrosis.